⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JUNS News
Jupiter Neurosciences, Inc. Common Stock
Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users
globenewswire.com
JUNS
Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference
accessnewswire.com
JUNS
DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event
accessnewswire.com
COE
ACCS
ASNS
DRTS
AREB
BKYI
FUFU
CJMB
DVLT
FBLG
MEHA
HCTI
INDO
JUNS
KAPA
LIXT
MYSZ
NNVC
HOVR
NOMA
OPTT
OWLS
PERF
PHIO
PROP
PRPO
SJ
LITM
SOPA
SNGX
XHLD
TYGO
TIVC
TRX
WGRX
WWR
ZENA
FLGC
DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event
accessnewswire.com
COE
ACCS
ASNS
DRTS
AREB
BKYI
FUFU
CJMB
DVLT
FBLG
MEHA
HCTI
INDO
JUNS
KAPA
LIXT
MYSZ
NNVC
HOVR
NOMA
OPTT
OWLS
PERF
PHIO
PROP
PRPO
SJ
LITM
SOPA
SNGX
XHLD
TYGO
TIVC
TRX
WGRX
WWR
ZENA
FLGC
DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event
accessnewswire.com
COE
ACCS
ASNS
DRTS
AREB
BKYI
FUFU
CJMB
DVLT
FBLG
MEHA
HCTI
INDO
JUNS
KAPA
LIXT
MYSZ
NNVC
HOVR
NOMA
OPTT
OWLS
PERF
PHIO
PROP
PRPO
SJ
LITM
SOPA
SNGX
XHLD
TYGO
TIVC
TRX
WGRX
WWR
ZENA
FLGC
DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event
accessnewswire.com
COE
ACCS
ASNS
DRTS
AREB
BKYI
FUFU
CJMB
DVLT
FBLG
MEHA
HCTI
INDO
JUNS
KAPA
LIXT
MYSZ
NNVC
HOVR
NOMA
OPTT
OWLS
PERF
PHIO
PROP
PRPO
SJ
LITM
SOPA
SNGX
XHLD
TYGO
TIVC
TRX
WGRX
WWR
ZENA
FLGC
Kaskela Law Firm Announces Stockholder Investigation of Jupiter Neurosciences, Inc. (NASDAQ:JUNS) and Encourages Long-Term JUNS Investors to Contact the Firm
accessnewswire.com
JUNS
Join Jupiter Neurosciences’ Exclusive Live Investor Webinar and Q&A Session on January 6
globenewswire.com
JUNS
SHAREHOLDER ALERT: Kaskela Law Firm Announces Investigation of Jupiter Neurosciences, Inc. (JUNS) And Encourages Current JUNS Shareholders to Contact The Firm
accessnewswire.com
JUNS
Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
globenewswire.com
JUNS